Literature DB >> 10901380

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells.

R Zeidler1, J Mysliwietz, M Csánady, A Walz, I Ziegler, B Schmitt, B Wollenberg, H Lindhofer.   

Abstract

Bispecific antibodies (bsAb) are considered as promising tools for the elimination of disseminated tumour cells in a minimal residual disease situation. The bsAb-mediated recruitment of an immune effector cell in close vicinity of a tumour cell is thought to induce an antitumoural immune response. However, classical bispecific molecules activate only a single class of immune effector cell that may not yield optimal immune responses. We therefore constructed an intact bispecific antibody, BiUII (anti-CD3 x anti-EpCAM), that not only recognizes tumour cells and T lymphocytes with its two binding arms, but also binds and activates Fcgamma-receptor positive accessory cells through its Fc-region. We have demonstrated recently that activated accessory cells contribute to the bsAb-induced antitumoural activity. We now analyse this stimulation in more detail and demonstrate here the BiUII-induced upregulation of activation markers like CD83 and CD95 on accessory cells and the induction of neopterin and biopterin synthesis. Experiments with pure cell subpopulations revealed binding of BiUII to CD64+ accessory cells and CD16+ NK cells, but not to CD32+ B lymphocytes. We provide further evidence for the importance of the Fc-region in that this bispecific molecule stimulates Fcgamma-R-positive accessory cells to eliminate tumour cells in vitro by direct phagocytosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10901380      PMCID: PMC2363488          DOI: 10.1054/bjoc.2000.1237

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing.

Authors:  R Zeidler; G Reisbach; B Wollenberg; S Lang; S Chaubal; B Schmitt; H Lindhofer
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

Review 2.  The dendritic cell system and its role in immunogenicity.

Authors:  R M Steinman
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

Review 3.  Going both ways: bispecific antibodies and targeted cellular cytotoxicity.

Authors:  M W Fanger; D M Segal; J R Wunderlich
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

4.  Analysis of the tetrahydrobiopterin synthesizing system during maturation of murine reticulocytes.

Authors:  F Kerler; L Hültner; I Ziegler; G Katzenmaier; A Bacher
Journal:  J Cell Physiol       Date:  1990-02       Impact factor: 6.384

5.  Induction of GTP-cyclohydrolase I mRNA expression by lectin activation and interferon-gamma treatment in human cells associated with the immune response.

Authors:  K Schott; M Gütlich; I Ziegler
Journal:  J Cell Physiol       Date:  1993-07       Impact factor: 6.384

6.  Production of a monoclonal antibody (K 931) to a squamous cell carcinoma associated antigen identified as the 17-1A antigen.

Authors:  J J Quak; G Van Dongen; J G Brakkee; D J Hayashida; A J Balm; G B Snow; C J Meijer
Journal:  Hybridoma       Date:  1990-08

7.  Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity.

Authors:  D S Heo; J G Park; K Hata; R Day; R B Herberman; T L Whiteside
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

8.  A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.

Authors:  L M Weiner; M Holmes; G P Adams; F LaCreta; P Watts; I Garcia de Palazzo
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

9.  Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism.

Authors:  I A Haagen; A J Geerars; M R Clark; J G van de Winkel
Journal:  J Immunol       Date:  1995-02-15       Impact factor: 5.422

10.  Resting and sensitized T lymphocytes exhibit distinct stimulatory (antigen-presenting cell) requirements for growth and lymphokine release.

Authors:  K Inaba; R M Steinman
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

View more
  46 in total

1.  Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.

Authors:  Klaus Pietzner; Ignace Vergote; Armando Santoro; Radoslav Chekerov; Frederik Marmé; Per Rosenberg; Holger Martinius; Hilke Friccius-Quecke; Jalid Sehouli
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.

Authors:  Eugen Dhimolea; Janice M Reichert
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

Review 3.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

Review 4.  Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

Authors:  Patrick Chames; Daniel Baty
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

Review 5.  Bispecific antibodies in cancer immunotherapy.

Authors:  Siqi Chen; Jing Li; Qing Li; Zhong Wang
Journal:  Hum Vaccin Immunother       Date:  2016-06-01       Impact factor: 3.452

Review 6.  Targeting T cells with bispecific antibodies for cancer therapy.

Authors:  Lawrence G Lum; Archana Thakur
Journal:  BioDrugs       Date:  2011-12-01       Impact factor: 5.807

7.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

8.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors:  Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

9.  Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.

Authors:  Peter Ruf; Michael Kluge; Michael Jäger; Alexander Burges; Constantin Volovat; Markus Maria Heiss; Jürgen Hess; Pauline Wimberger; Birgit Brandt; Horst Lindhofer
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

10.  Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.

Authors:  Jalid Sehouli; Klaus Pietzner; Pauline Wimberger; Ignace Vergote; Per Rosenberg; Andreas Schneeweiss; Carsten Bokemeyer; Christoph Salat; Giovanni Scambia; Dominique Berton-Rigaud; Armando Santoro; Andrés Cervantes; Olivier Trédan; Christophe Tournigand; Nicoletta Colombo; Alexander S Dudnichenko; Anneke Westermann; Hilke Friccius-Quecke; Florian Lordick
Journal:  Med Oncol       Date:  2014-06-26       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.